Outcomes of Transsphenoidal Microsurgery for Prolactinomas – A Contemporary Series of 162 Cases

Abstract

Introduction Renewed interest in transsphenoidal surgery (TSS) as a therapeutic option for prolactinomas has emerged. This study is aimed at defining the current role of pituitary surgery in the management of prolactinomas.

Materials and Methods In this retrospective, consecutive single-center study, 162 patients who underwent primary microscopic TSS for prolactinomas between 2006 and 2019 were analyzed regarding surgical indication, previous dopamine-agonist (DA) treatment, early remission rates (3 months postoperatively), surgical complications and pituitary function.

Results Seventy-four microprolactinomas and 88 macroprolactinomas were operated by TSS. 62.3% of the patients had received prior DA treatment. For microprolactinomas, the predominant indication for surgery was patient’s wish (41.9%), while indications for macroprolactinomas varied. For enclosed microprolactinomas, the initial remission rate was 92.1%, while for macroprolactinomas, the rate was 70.4%. No significant difference of remission rates was found between DA-pretreated (65.3%) and non-pretreated (72.1%) patients (p=0.373).None of the patients suffered a significant complication. Re-operation for a postoperative cerebrospinal fluid leak was required in one patient (0.6%). Permanent postoperative deterioration of pituitary function was only observed in one of 158 patients with surgery for a prolactinoma (0.6%). Improvement of pituitary function was observed in 8 of 25 patients (32%) with preoperative deficits.

Conclusion Transsphenoidal microsurgery is safe and efficient for treatment of prolactinomas. It is particularly suitable for enclosed prolactinomas. The patient should be well informed of the pros and cons of the treatment options, which include DA medication and TSS, and the patient’s preference should be taken into account during decision-making.

Key words

surgery - dopamine-agonists - prolactin - remission - hypopituitarism - surgical complication

Publication History

Received: 25 May 2020
Received: 05 August 2020

Accepted: 25 August 2020

Article published online:
18 January 2021

• References

• 1 Webster J, Piscitelli G, Polli A. et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. The New England Journal of Medicine 1994; 331: 904-909
• 2 Amar AP, Couldwell WT, Chen JC. et al. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. Journal of Neurosurgery 2002; 97: 307-314
• 3 Kreutzer J, Buslei R, Wallaschofski H. et al. 2008; Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. European Journal of Endocrinology 2008: 11-18
• 4 Sinha S, Sharma BS, Mahapatra AK. Microsurgical management of prolactinomas – clinical and hormonal outcome in a series of 172 cases. Neurology India 2011; 59: 532-536
• 5 Dekkers OM, Lagro J, Burman P. et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. The Journal of Clinical Endocrinology and Metabolism 2010; 95: 43-51
• 6 Gillam MP, Molitch ME, Lombardi G. et al. Advances in the treatment of prolactinomas. Endocrine reviews 2006; 27: 485-534
• 7 Wong A, Eloy JA, Couldwell WT. et al. Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia 2015; 22: 1562-1567
• 8 Kars M, Pereira AM, Smit JW. et al. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. European Journal of Internal Medicine 2009; 20: 387-393
• 9 Vroonen L, Lancellotti P, Garcia MT. et al. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. Endocrine 2017; 55: 239-245
• 10 Zanettini R, Antonini A, Gatto G. et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. The New England Journal of Medicine 2007; 356: 39-46
• 11 Valassi E, Klibanski A, Biller BM. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. The Journal of Clinical Endocrinology and Metabolism 2010; 95: 1025-1033
• 12 Auriemma RS, Pivonello R, Perone Y. et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. European Journal of Endocrinology 2013; 169: 359-366
• 13 Caputo C, Prior D, Inder WJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. The lancet Diabetes & Endocrinology 2015; 3: 906-913
• 14 Budayr A, Tan TC, Lo JC. et al. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study. BMC Endocrine Disorders 2020; 20: 25
• 15 Honegger J, Nasi-Kordhishti I, Aboutaha N. et al. Surgery for prolactinomas: a better choice?. Pituitary 2020; 23: 45-51
• 16 Ammirati M, Wei L, Ciric I. Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery, and Psychiatry 2013; 84: 843-849
• 17 Tampourlou M, Trifanescu R, Paluzzi A. et al. Therapy of endocrine disease: Surgery in microprolactinomas: effectiveness and risks based on contemporary literature. European Journal of Endocrinology 2016; 175: R89-R96
• 18 Honegger J, Grimm F. The experience with transsphenoidal surgery and its importance to outcomes. Pituitary 2018; 21: 545-555
• 19 Loyo-Varela M, Herrada-Pineda T, Revilla-Pacheco F. et al. Pituitary tumor surgery: review of 3004 cases. World Neurosurgery 2013; 79: 331-336
• 20 Knosp E, Steiner E, Kitz K. et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993; 33: 610-617 discussion 617-618
• 21 Casanueva FF, Molitch ME, Schlechte JA. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology 2006; 65: 265-273
• 22 Shimon I. Giant Prolactinomas. Neuroendocrinology 2019; 109: 51-56
• 23 Losa M, Mortini P, Barzaghi R. et al. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. The Journal of Clinical Endocrinology and Metabolism 2002; 87: 3180-3186
• 24 Ikeda H, Watanabe K, Tominaga T. et al. Transsphenoidal microsurgical results of female patients with prolactinomas. Clinical Neurology and Neurosurgery 2013; 115: 1621-1625
• 25 Vroonen L, Jaffrain-Rea ML, Petrossians P. et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology 2012; 167: 651-662
• 26 Landolt AM, Keller PJ, Froesch ER. et al. Bromocriptine: Does it jeopardise the result of later surgery for prolactinomas?. Lancet 1982; 2: 657-658
• 27 Tamasauskas A, Sinkunas K, Bunevicius A. et al. Transsphenoidal surgery for microprolactinomas in women: Results and prognosis. Acta Neurochirurgica 2012; 154: 1889-1893
• 28 Primeau V, Raftopoulos C, Maiter D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. European Journal of Endocrinology 2012; 166: 779-786
• 29 Fatemi N, Dusick JR, Mattozo C. et al. Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Neurosurgery 2008; 63: 709-718 discussion 718-709
• 30 Glezer A, Bronstein MD. Prolactinomas, cabergoline, and pregnancy. Endocrine 2014; 47: 64-69
• 31 Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. European Journal of Endocrinology 2015; 172: R205-R213